Literature DB >> 15565631

Fluoxetine increases extracellular levels of 3-methoxy-4-hydroxyphenylglycol in cultured COLO320 DM cells.

Chung-Tai Yue1, Yu-Li Liu.   

Abstract

Fluoxetine (Prozac) is a serotonin reuptake inhibitor. It increases extracellular levels of serotonin and is used in relieving the depressive symptoms of cancer patients. It has been reported that the drug may enhance the growth of certain cancer cells. This study investigates whether fluoxetine enhances the growth of a human colon cancer cell line (COLO320 DM) and if it affects the extracellular levels of serotonin or its metabolite, 5-hydroxyindole-3-acetic acid (5-HIAA) and other monoamines and metabolites at two cell densities. The extracellular levels of serotonin, 5-HIAA and other monoamines and metabolites were measured simultaneously by high performance liquid chromatography from cell-culture media after incubation of cells both with and without fluoxetine for 3 days. The viability of COLO320 DM cells was evaluated using 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). At low cell densities (1.25x10(5) cells ml-1), fluoxetine at 1-10 microM significantly increased the extracellular levels of serotonin (p<0.005), 5-HIAA (p<0.005), and 3-methoxy-4-hydroxyphenylglycol (MHPG; p<0.001) as compared to the controls. Fluoxetine at 10-100 microM significantly inhibited the growth of COLO320 DM (p<0.005). At high cell densities (2x10(6) cells ml-1), fluoxetine at 1-10 microM significantly increased the extracellular levels of MHPG (p<0.01), and at 10 microM it significantly increased the extracellular levels of 5-HIAA (p<0.05). Fluoxetine at 100 microM significantly inhibited the growth of the cells (p<0.0001). These results suggest that fluoxetine at 1 microM of effective concentration may increase the extracellular levels MHPG, in addition to serotonin and 5-HIAA levels, yet not inhibit the growth of COLO320 DM. Copyright (c) 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15565631     DOI: 10.1002/cbf.1193

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  6 in total

1.  Colorectal cancer risk in relation to antidepressant medication use.

Authors:  Jessica Chubak; Denise M Boudreau; Stephen J Rulyak; Margaret T Mandelson
Journal:  Int J Cancer       Date:  2011-01-01       Impact factor: 7.396

2.  Antidepressant Use and Risk of Colorectal Cancer in the Women's Health Initiative.

Authors:  Jenna F Kiridly-Calderbank; Susan R Sturgeon; Candyce H Kroenke; Katherine W Reeves
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-22       Impact factor: 4.254

3.  Plasma serotonin level is a predictor for recurrence and poor prognosis in colorectal cancer patients.

Authors:  Yan Xia; Dawei Wang; Nan Zhang; Zhihao Wang; Li Pang
Journal:  J Clin Lab Anal       Date:  2017-05-22       Impact factor: 2.352

4.  Anti-mitogenic and apoptotic effects of 5-HT1B receptor antagonist on HT29 colorectal cancer cell line.

Authors:  Ramin Ataee; Soheila Ajdary; Mohammadreza Zarrindast; Mehdi Rezayat; Mohammad Reza Hayatbakhsh
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-21       Impact factor: 4.553

Review 5.  Antidepressant fluoxetine and its potential against colon tumors.

Authors:  Helga Stopper; Sergio Britto Garcia; Ana Maria Waaga-Gasser; Vinicius Kannen
Journal:  World J Gastrointest Oncol       Date:  2014-01-15

6.  Antidepressant use and colorectal cancer risk.

Authors:  Patricia F Coogan; Brian L Strom; Lynn Rosenberg
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-11       Impact factor: 2.890

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.